"In patients with metastatic castration-resistant prostate cancer, researchers have found that androgen receptor pathway inhibitors (ARPIs) outperformed the standard of care, which improved responses to treatment and overall survival (OS; time a patient lives, regardless of disease status)."
We are talking about sequential therapy in this case, triplet is a different story (and it's used in castration sensitive setting).
„ARPIs May Improve Survival in Some With Prostate Cancer“ - that is why they got an FDA approval! The editor of this article in cure magazine has misunderstood the press release.
It refers to the ProBio trial news-release: eurekalert.org/news-release... The ProBio trial has been published in nature: nature.com/articles/s41591-...
The trial did DNA tests to determine biomarker signatures to decide if the CRPC patient should be treated with chemo or ARPIs. There was a control arm called physician's choice which meant the therapy the physician would typically recommend for his patient. The trial was done to determine if a biomarker–treatment combination is superior compared to a physician’s choice of treatment within that biomarker or patient group.
If the patients got one of these therapies based on the biomarker signatures, ARPIs demonstrated a longer overall survival of 38.7 months compared to 21.7 months for chemo and 21.8 months for the physician’s choice control group.
The trial was presented at ESMO 2023: urotoday.com/conference-hig... There is also an interview with Dr. Grönberg urotoday.com/video-lectures...
Here is the ProBio trial on X: x.com/ProBioTrial
5 Challenges to Conventional Wisdom in Prostate Cancer
New hope for survival prostate cancer with curcuminTreatment After Progression in Metastatic Castration-Resistant Prostate Cancer: some options
New prostate cancer treatment conceptExamining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with mHSPC
